Amolyt Pharma completes acquisition by AstraZeneca

AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion

18-Jul-2024 - Andera Partners announced that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company ...

Cellectis enters into strategic collaboration and investment agreement with AstraZeneca

Cellectis to receive up to $245M in cash, with potential for additional milestones, plus tiered royalties

03-Nov-2023 - Cellectis announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agreement”, (ii) an investment agreement relating to an initial equity investment of $80M, and (iii) a memorandum of understanding (the “MOU”) relating to an additional equity investment of ...

Dako and Quintiles form alliance to speed development of personalized medicine

02-Nov-2010 - Dako and Quintiles announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion ...

Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement

17-Jun-2009 - Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications. The new agreement calls for Cenix to complete at ...

First statin monotherapy to achieve regression of coronary atherosclerosis by angiography in a major clinical study

03-Apr-2008 - According to AstraZeneca, CRESTOR(R) (rosuvastatin) is the only statin to show regression of coronary atherosclerosis in a major clinical study. That result, which was based on intravascular ultrasound (IVUS) data from the ASTEROID study, has now been expanded upon by quantitative coronary ...

Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery.

25-Mar-2008 - Cenix BioScience GmbH (Dresden) announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latter¹s efforts in the discovery and validation of novel therapeutic drug targets. Cenix will apply its well-established expertise in combining high ...

Astra Zeneca opens new US$25M pharmaceutical R&D facility for investigational products at Macclesfield, Cheshire, UK

23-Jun-2003 - New research and development (R&D) facilities, worth around US$25 million (£16 million), were officially opened at AstraZeneca's Macclesfield site by the Company's Executive VP Global Development, Dr Martin Nicklasson. The investment provides an integrated facility for pharmaceutical and ...

120,000 Swedish Twins Could Help Unlock the Secrets of the World's Diseases

AstraZeneca to Collaborate with the Karolinska Institute on New Bio Bank

28-Jun-2002 - Drug discovery just got a boost at AstraZeneca, where a new collaboration with the Karolinska Institute will give the global pharmaceutical company access to a unique collection of medical and environmental exposure information from a database of more than 120,000 Swedish twins. As the first ...